tradingkey.logo
๎™ผ
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™

Janux Therapeutics Inc

JANX
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
11.370USD
-0.125-1.09%
์ข…๊ฐ€ย 11-13 16:00๏ผˆET๏ผ‰
695.16M์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM

Janux Therapeutics Inc ์ •๋ณด ํšŒ์‚ฌ

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

Janux Therapeutics Inc ํ”„๋กœํ•„

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ JANX
ํšŒ์‚ฌ ์ด๋ฆ„Janux Therapeutics Inc
์ƒ์žฅ์ผJun 11, 2021
CEOCampbell (David)
์ง์› ์ˆ˜74
์œ ํ˜•Ordinary Share
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒJun 11
์ฃผ์†Œ10955 Vista Sorrento Parkway
๋„์‹œSAN DIEGO
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐ€United States of America
์šฐํŽธ ๋ฒˆํ˜ธ92130
์ „ํ™”18587514493
์›น์‚ฌ์ดํŠธhttps://www.januxrx.com/
์ข…๋ชฉ ์ฝ”๋“œ JANX
์ƒ์žฅ์ผJun 11, 2021
CEOCampbell (David)

Janux Therapeutics Inc์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Dr. Sheila Gujrathi, M.D.
Dr. Sheila Gujrathi, M.D.
Independent Director
Independent Director
112.64K
-3.33%
Ms. Natasha A. Hernday
Ms. Natasha A. Hernday
Independent Director
Independent Director
8.40K
+65.49%
Mr. Eric L. Dobmeier, J.D.
Mr. Eric L. Dobmeier, J.D.
Independent Director
Independent Director
8.40K
+65.49%
Dr. Ronald W. (Ron) Barrett, Ph.D.
Dr. Ronald W. (Ron) Barrett, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.00K
+68.75%
Dr. Jake Simson, Ph.D.
Dr. Jake Simson, Ph.D.
Independent Director
Independent Director
8.00K
+68.75%
Dr. David Campbell, Ph.D.
Dr. David Campbell, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
--
Mr. Andy Meyer
Mr. Andy Meyer
Chief Business Officer
Chief Business Officer
--
--
Dr. Thomas Diraimondo, Ph.D.
Dr. Thomas Diraimondo, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
--
--
Ms. Alana B. Mcnulty
Ms. Alana B. Mcnulty
Independent Director
Independent Director
--
--
Ms. Vickie L. Capps, CPA
Ms. Vickie L. Capps, CPA
Independent Director
Independent Director
--
--
๋” ๋ณด๊ธฐ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Dr. Sheila Gujrathi, M.D.
Dr. Sheila Gujrathi, M.D.
Independent Director
Independent Director
112.64K
-3.33%
Ms. Natasha A. Hernday
Ms. Natasha A. Hernday
Independent Director
Independent Director
8.40K
+65.49%
Mr. Eric L. Dobmeier, J.D.
Mr. Eric L. Dobmeier, J.D.
Independent Director
Independent Director
8.40K
+65.49%
Dr. Ronald W. (Ron) Barrett, Ph.D.
Dr. Ronald W. (Ron) Barrett, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.00K
+68.75%
Dr. Jake Simson, Ph.D.
Dr. Jake Simson, Ph.D.
Independent Director
Independent Director
8.00K
+68.75%
Dr. David Campbell, Ph.D.
Dr. David Campbell, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
--

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Janux Therapeutics Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋ˆ„๊ตฌ์ธ๊ฐ€์š”?

๎™Œ
Janux Therapeutics Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค: Dr. Sheila Gujrathi, M.D.

Janux Therapeutics Inc(JANX)์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ๋ช‡ ๊ฐœ์ž…๋‹ˆ๊นŒ?

๎™Œ
2026Q1 ๊ธฐ์ค€์œผ๋กœ, Janux Therapeutics Inc์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ์ด 461๊ณณ์ด๋ฉฐ, ์ด๋“ค์ด ๋ณด์œ ํ•œ ์ฃผ์‹์˜ ์ด ๊ฐ€์น˜๋Š” ์•ฝ 67.20M๋กœ ์ „์ฒด ๋ฐœํ–‰ ์ฃผ์‹์˜ 110.21%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค. ์ด๋Š” 2025Q4 ๋Œ€๋น„ -10275276.00 ์ฆ๊ฐ€ํ•œ ์ˆ˜์น˜์ž…๋‹ˆ๋‹ค.
tradingkey.logo
์œ„ํ—˜ ๊ฒฝ๊ณ : ์ €ํฌ ์›น์‚ฌ์ดํŠธ์™€ ๋ชจ๋ฐ”์ผ ์•ฑ์€ ํŠน์ • ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ผ๋ฐ˜์ ์ธ ์ •๋ณด๋งŒ์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. Finsights๋Š” ์žฌ์ •์  ์กฐ์–ธ์ด๋‚˜ ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜์ง€ ์•Š์œผ๋ฉฐ, ์ด๋Ÿฌํ•œ ์ •๋ณด ์ œ๊ณต์ด Finsights๊ฐ€ ๊ธˆ์œต ์กฐ์–ธ์ด๋‚˜ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜๋Š” ๊ฒƒ์œผ๋กœ ํ•ด์„๋˜์–ด์„œ๋Š” ์•ˆ ๋ฉ๋‹ˆ๋‹ค.
ํˆฌ์ž ์ƒํ’ˆ์€ ํˆฌ์ž ์›๊ธˆ ์†์‹ค์„ ํฌํ•จํ•œ ์ƒ๋‹นํ•œ ํˆฌ์ž ์œ„ํ—˜์— ๋…ธ์ถœ๋˜์–ด ์žˆ์œผ๋ฉฐ, ๋ชจ๋“  ์‚ฌ๋žŒ์—๊ฒŒ ์ ํ•ฉํ•˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํˆฌ์ž ์ƒํ’ˆ์˜ ๊ณผ๊ฑฐ ์„ฑ๊ณผ๋Š” ๋ฏธ๋ž˜ ์„ฑ๊ณผ๋ฅผ ๋ณด์žฅํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
Finsights๋Š” ์ œ3์ž ๊ด‘๊ณ ์ฃผ๋‚˜ ์ œํœด์‚ฌ๊ฐ€ ์ €ํฌ ์›น์‚ฌ์ดํŠธ๋‚˜ ๋ชจ๋ฐ”์ผ ์•ฑ ๋˜๋Š” ๊ทธ ์ผ๋ถ€์— ๊ด‘๊ณ ๋ฅผ ๊ฒŒ์žฌํ•˜๊ฑฐ๋‚˜ ์ „๋‹ฌํ•  ์ˆ˜ ์žˆ๋„๋ก ํ—ˆ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์‚ฌ์šฉ์ž๊ฐ€ ๊ด‘๊ณ ์™€ ์ƒํ˜ธ์ž‘์šฉํ•˜๋Š” ๋ฐฉ์‹์— ๋”ฐ๋ผ ์ด๋“ค๋กœ๋ถ€ํ„ฐ ๋ณด์ƒ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
ยฉ ์ €์ž‘๊ถŒ: FINSIGHTS MEDIA PTE. LTD. ๋ชจ๋“  ๊ถŒ๋ฆฌ ๋ณด์œ